These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
123 related items for PubMed ID: 9060795
1. Beneficial effects of a Ca2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: comparison with dobutamine and phosphodiesterase inhibitor. Takaoka H, Takeuchi M, Hata K, Hayashi Y, Mori M, Yamakawa H, Yamaguchi K, Yokoyama M. Am Heart J; 1997 Mar; 133(3):283-9. PubMed ID: 9060795 [Abstract] [Full Text] [Related]
2. Oxygen-saving effect of a new cardiotonic agent, MCI-154, in diseased human hearts. Mori M, Takeuchi M, Takaoka H, Hata K, Hayashi Y, Yamakawa H, Yokoyama M. J Am Coll Cardiol; 1997 Mar 01; 29(3):613-22. PubMed ID: 9060901 [Abstract] [Full Text] [Related]
3. Comparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseases human heart. Takaoka H, Takeuchi M, Odake M, Hayashi Y, Mori M, Hata K, Yokoyama M. J Am Coll Cardiol; 1993 Aug 01; 22(2):598-606. PubMed ID: 8335835 [Abstract] [Full Text] [Related]
4. Effects of a novel inotropic agent, BAY y 5959, in conscious dogs: comparison with dobutamine and milrinone. Sato N, Uechi M, Asai K, Patrick T, Kudej RK, Vatner SF. Am J Physiol; 1997 Feb 01; 272(2 Pt 2):H753-9. PubMed ID: 9124435 [Abstract] [Full Text] [Related]
9. Lusitropic effects of a Ca2+ sensitization with a new cardiotonic agent, MCI-154, on diseased human hearts. Mori M, Takeuchi M, Takaoka H, Yokoyama M. Cardiovasc Res; 1995 Dec 01; 30(6):915-22. PubMed ID: 8746206 [Abstract] [Full Text] [Related]
11. Alteration in energetics in patients with left ventricular dysfunction after myocardial infarction: increased oxygen cost of contractility. Hayashi Y, Takeuchi M, Takaoka H, Hata K, Mori M, Yokoyama M. Circulation; 1996 Mar 01; 93(5):932-9. PubMed ID: 8598084 [Abstract] [Full Text] [Related]
12. Hemodynamic, neurohumoral, and myocardial energetic effects of pimobendan, a novel calcium-sensitizing compound, in patients with mild to moderate heart failure. Remme WJ, Kruijssen DA, van Hoogenhuyze DC, Krauss XH, Bartels GL, Storm CJ, de Leeuw PW. J Cardiovasc Pharmacol; 1994 Nov 01; 24(5):730-9. PubMed ID: 7532750 [Abstract] [Full Text] [Related]
13. Oxygen-wasting effect of inotropy: is there a need for a new evaluation? An experimental large-animal study using dobutamine and levosimendan. Müller S, How OJ, Jakobsen Ø, Hermansen SE, Røsner A, Stenberg TA, Myrmel T. Circ Heart Fail; 2010 Mar 01; 3(2):277-85. PubMed ID: 20018954 [Abstract] [Full Text] [Related]
14. Comparative haemodynamic and metabolic effects of vasodilator and inotropic agents in experimental myocardial infarction. Franciosa JA, Notargiacomo AV, Cohn JN. Cardiovasc Res; 1978 May 01; 12(5):294-302. PubMed ID: 679229 [Abstract] [Full Text] [Related]
15. Haemodynamic effects of dobutamine in patients with congestive heart failure receiving captopril. Ikram H, Maslowski AH, Nicholls MG. Br Heart J; 1981 Nov 01; 46(5):528-30. PubMed ID: 7032556 [Abstract] [Full Text] [Related]
16. Effect of phosphodiesterase III inhibitor on contractility, afterload, and vascular capacitance during right heart bypass preparation. Tanoue Y, Morita S, Nagano I, Ochiai Y, Tominaga R, Kawachi Y, Yasui H. Jpn J Thorac Cardiovasc Surg; 2001 Oct 01; 49(10):607-13. PubMed ID: 11692586 [Abstract] [Full Text] [Related]
17. Different response of oxygen consumption and cardiac output to various endogenous and synthetic catecholamines in awake dogs. Scheeren TW, Arndt JO. Crit Care Med; 2000 Dec 01; 28(12):3861-8. PubMed ID: 11153627 [Abstract] [Full Text] [Related]